Synthesis, structure, and screening of estrogenic and antiestrogenic activity of new 3,17-substituted-16,17-seco-estratriene derivatives.
The starting compound for synthesis of new 16,17-seco-estratriene derivatives was 3-benzyloxy-17-hydroxy-16,17-secoestra-1,3,5(10)-triene-16-nitrile (1b), obtained from estrone in several synthetic steps. 17-Tosyl, -chloro-, bromo-, and -iodo- derivatives 2b, 4b, 5b, and 6b were prepared directly from secocyanoalcohol 1b, while the 17-fluoro-derivative 3b was obtained from tosylate 2b in the reaction with tetrabutyl ammonium fluoride. The corresponding 3-hydroxy derivatives of these compounds were produced by action of hydrogen in presence of Pd/C, except the 3-hydroxy-17-iodo derivative 6a, which was obtained from 3-hydroxy-17-tosyloxy derivative 2a. All the newly synthesized compounds in biological tests on experimental animals exhibited an almost total loss of estrogenic activity, while most of them even prevented the action of endogenous estrogens. On the other hand, most of them, except compounds 3a and 6b, partially hindered the action of estradiol benzoate, behaving as moderate antagonists.
Jovanović-Santa
Suzana
S
Department of Chemistry, Faculty of Science, University of Novi Sad, Trg Dositeja Obradovića 3, Serbia and Montenegro, 21000 Novi Sad, Yugoslavia. santas@ih.ns.ac.yu
Petrović
Julijana
J
Andrić
Silvana
S
Kovacević
Radmila
R
Durendić
Evgenija
E
Sakac
Marija
M
Lazar
Dusan
D
Stanković
Slobodanka
S
D000818:Animals; D018360:Crystallography, X-Ray; D004353:Drug Evaluation, Preclinical; D004963:Estrenes / Q000138:chemical synthesis / Q000494:pharmacology*; D004965:Estrogen Antagonists / Q000138:chemical synthesis / Q000494:pharmacology*; D004967:Estrogens / Q000138:chemical synthesis / Q000494:pharmacology; D005260:Female; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D012632:Secosteroids / Q000138:chemical synthesis / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D013629:Tamoxifen / Q000494:pharmacology; D014599:Uterus / Q000187:drug effects / Q000254:growth & development
D004963:Estrenes; D004965:Estrogen Antagonists; D004967:Estrogens; D012632:Secosteroids; D013629:Tamoxifen